Ruboxistaurin

Generic Name
Ruboxistaurin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H28N4O3
CAS Number
169939-94-0
Unique Ingredient Identifier
721809WQCP
Background

Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Ruboxistaurin in New York Heart Failure Classification III-IV Patients

Phase 1
Withdrawn
Conditions
Heart Failure
Interventions
Drug: Ruboxistaurin
First Posted Date
2016-05-11
Last Posted Date
2022-06-06
Lead Sponsor
University of Tennessee
Registration Number
NCT02769611
Locations
🇺🇸

The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

First Posted Date
2008-09-30
Last Posted Date
2008-09-30
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
30
Registration Number
NCT00761852

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Phase 3
Completed
Conditions
Diabetic Retinopathy
Interventions
Drug: placebo
Drug: ruboxistaurin
First Posted Date
2008-01-30
Last Posted Date
2016-10-06
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
685
Registration Number
NCT00604383
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: ruboxistaurin
Other: placebo
First Posted Date
2007-11-01
Last Posted Date
2016-07-26
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
48
Registration Number
NCT00552227
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States

Effect of LY333531 on Vascular and Neural Functions

Phase 2
Completed
Conditions
Diabetes Mellitus
First Posted Date
2007-06-06
Last Posted Date
2016-07-26
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
30
Registration Number
NCT00482976
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States

Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: ruboxistaurin
Drug: placebo
First Posted Date
2006-02-28
Last Posted Date
2016-08-29
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
20
Registration Number
NCT00297401
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada

Treatment for Completers of the Study B7A-MC-MBCM

Phase 3
Completed
Conditions
Diabetic Retinopathy
Interventions
Drug: Ruboxistaurin
First Posted Date
2005-12-19
Last Posted Date
2016-10-06
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
203
Registration Number
NCT00266695
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Madison, Wisconsin, United States

The Effect of Ruboxistaurin on Small Fiber Function

Phase 2
Completed
Conditions
Diabetic Neuropathy
First Posted Date
2005-09-19
Last Posted Date
2016-07-26
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
52
Registration Number
NCT00190970
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Norfolk, Virginia, United States

Effect of Ruboxistaurin on Clinically Significant Macular Edema

Phase 3
Completed
Conditions
Diabetic Macular Edema
Interventions
Drug: Placebo
Drug: Ruboxistaurin
First Posted Date
2005-08-24
Last Posted Date
2016-10-06
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
309
Registration Number
NCT00133952
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Phase 3
Completed
Conditions
Diabetic Retinopathy
Interventions
Drug: placebo
Drug: ruboxistaurin
First Posted Date
2004-08-31
Last Posted Date
2016-10-06
Lead Sponsor
Chromaderm, Inc.
Target Recruit Count
731
Registration Number
NCT00090519
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy